Ncardia
Charles Jacques serves as the Chief Financial Officer at both Cellistic and Ncardia, bringing expertise in financial leadership within the cell therapy and human iPSC technology sectors. In addition to these roles, Jacques holds a position as a Board Member at Rhizome Network, a Contract Research Organization in agriculture, and operates CJA Consulting SRL, providing financial consulting services. Previous experience includes a directorial role at EKKOFIN, finance transformation consulting at Imcyse SA, and finance leadership at Catalent Pharma Solutions and MaSTherCell, where Jacques significantly contributed to financial planning, strategy, and compliance in fast-paced biopharmaceutical environments. Academic credentials were earned from Université de Namur.
This person is not in any offices
Ncardia
Ncardia is a drug discovery company and expert in human iPSC technology. We operate worldwide with facilities, offices and staff throughout Europe and North America. We work with biopharmaceutical companies in drug discovery worldwide, to leverage the power of stem cell technologies in the development of novel therapies of multiple modalities at any stage of development. Over the past 10 years, we have built the expertise and infrastructure required to differentiate, manufacture and characterize high-quality iPSC-derived cell and disease models. We can facilitate the process of disease modeling and high-throughput screening to accelerate drug discovery. We listen to our customer’s project plans, questions and challenges, and co-develop human iPSC-based solutions that fit their specifications. Explore our website to learn more www.ncardia.com.